sentence
stringlengths 27
1.01k
| drug1
stringlengths 2
46
| drug2
stringlengths 2
63
| relation
stringclasses 5
values | source_file
stringclasses 566
values | sentence_id
stringlengths 17
21
| pair_id
stringlengths 20
26
|
|---|---|---|---|---|---|---|
In a multiple dose study of theophylline (400 mg once daily for 3 days) and cetirizine (20 mg once daily for 3 days), a 16% decrease in the clearance of cetirizine was observed.
|
theophylline
|
cetirizine
|
MECHANISM
|
Cetirizine_ddi.xml
|
DDI-DrugBank.d393.s2
|
DDI-DrugBank.d393.s2.p0
|
Lithium carbonate: The stimulatory effects of amphetamines may be inhibited by lithium carbonate.
|
Lithium carbonate
|
amphetamines
|
NONE
|
Dextroamphetamine_ddi.xml
|
DDI-DrugBank.d236.s19
|
DDI-DrugBank.d236.s19.p0
|
In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.
|
furosemide
|
FLOLAN
|
MECHANISM
|
Epoprostenol_ddi.xml
|
DDI-DrugBank.d241.s3
|
DDI-DrugBank.d241.s3.p46
|
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.
|
quinolone
|
sucralfate
|
MECHANISM
|
Ciprofloxacin_ddi.xml
|
DDI-DrugBank.d123.s8
|
DDI-DrugBank.d123.s8.p4
|
Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.
|
rifampin
|
phenobarbital
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s8
|
DDI-DrugBank.d94.s8.p38
|
The pharmacokinetics and protein binding of fosphenytoin, phenytoin, and diazepam were not altered when diazepam and Cerebyx were concurrently administered in single submaximal doses.
|
phenytoin
|
Cerebyx
|
NONE
|
Fosphenytoin_ddi.xml
|
DDI-DrugBank.d40.s4
|
DDI-DrugBank.d40.s4.p6
|
Anticonvulsants (carbamazepine, felbamate, phenobarbital, phenytoin, topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.
|
felbamate
|
ethinyl estradiol
|
MECHANISM
|
Ethynodiol Diacetate_ddi.xml
|
DDI-DrugBank.d485.s12
|
DDI-DrugBank.d485.s12.p16
|
Compounds in these categories result in a decreased efficacy of bromocriptine mesylate: phenothiazines, haloperidol, metoclopramide, pimozide.
|
bromocriptine mesylate
|
metoclopramide
|
EFFECT
|
Bromocriptine_ddi.xml
|
DDI-DrugBank.d272.s2
|
DDI-DrugBank.d272.s2.p2
|
In vivo studies: Nitrates: The blood pressure lowering effects of sublingual nitrates (0.4 mg) taken 1 and 4 hours after vardenafil and increases in heart rate when taken at 1, 4 and 8 hours were potentiated by a 20 mg dose of Vardenafil in healthy middle-aged subjects.
|
Nitrates
|
nitrates
|
NONE
|
Vardenafil_ddi.xml
|
DDI-DrugBank.d198.s22
|
DDI-DrugBank.d198.s22.p0
|
Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.
|
Benzthiazide
|
lithium
|
INT
|
Benzthiazide_ddi.xml
|
DDI-DrugBank.d208.s0
|
DDI-DrugBank.d208.s0.p3
|
- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
|
Relafen
|
Daypro
|
NONE
|
Glimepiride_ddi.xml
|
DDI-DrugBank.d521.s2
|
DDI-DrugBank.d521.s2.p280
|
Other depressasnts such as alcohol, barbiturates, and MAOIs may enhance CNS depression when administered with ethchlorvynol.
|
MAOIs
|
ethchlorvynol
|
EFFECT
|
Ethchlorvynol_ddi.xml
|
DDI-DrugBank.d405.s1
|
DDI-DrugBank.d405.s1.p5
|
When other antiplatelet agents or anticoagulants are used concomitantly, there is the potential for FLOLAN to increase the risk of bleeding.
|
antiplatelet agents
|
FLOLAN
|
EFFECT
|
Epoprostenol_ddi.xml
|
DDI-DrugBank.d241.s1
|
DDI-DrugBank.d241.s1.p1
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
oxyphenbutazone
|
sulindac
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p1307
|
Therefore, a slower onset can be anticipated if STADOL NS is administered concomitantly with, or immediately following, a nasal vasoconstrictor.
|
STADOL NS
|
nasal vasoconstrictor
|
EFFECT
|
Butorphanol_ddi.xml
|
DDI-DrugBank.d246.s14
|
DDI-DrugBank.d246.s14.p0
|
Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
|
nefazodone
|
protease inhibitors
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s4
|
DDI-DrugBank.d94.s4.p298
|
Chlorthalidone and related drugs may increase the responsiveness to tubocurarine.
|
Chlorthalidone
|
tubocurarine
|
EFFECT
|
Chlorthalidone_ddi.xml
|
DDI-DrugBank.d265.s7
|
DDI-DrugBank.d265.s7.p0
|
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.
|
acetaminophen
|
valproic acid
|
NONE
|
11206047.xml
|
DDI-MedLine.d111.s5
|
DDI-MedLine.d111.s5.p56
|
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, amikacin), amphotericin B, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), tacrolimus, vancomycin.
|
tacrolimus
|
vancomycin
|
NONE
|
Adefovir Dipivoxil_ddi.xml
|
DDI-DrugBank.d244.s0
|
DDI-DrugBank.d244.s0.p35
|
Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
|
dopamine agonists
|
insulin
|
NONE
|
Levothyroxine_ddi.xml
|
DDI-DrugBank.d411.s4
|
DDI-DrugBank.d411.s4.p354
|
In ewes given 40 mg of phenobarbital sodium/kg for 5 days intraperitoneally (IP), the anticholinesterase effect of 4 mg of coumaphos/kg was significantly reduced and signs of toxicity were not present.
|
phenobarbital sodium
|
coumaphos
|
EFFECT
|
46730.xml
|
DDI-MedLine.d5.s4
|
DDI-MedLine.d5.s4.p0
|
Clonidine hydrochloride may enhance the CNS-depressive effects of alcohol, barbiturates or other sedatives.
|
Clonidine hydrochloride
|
barbiturates
|
EFFECT
|
Clonidine_ddi.xml
|
DDI-DrugBank.d495.s1
|
DDI-DrugBank.d495.s1.p1
|
Endothelium-intact aortic rings from high-estradiol rats were supersensitive to noradrenaline when compared to vehicle-, progesterone- and progesterone + high-estradiol-treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively).
|
estradiol
|
noradrenaline
|
EFFECT
|
11213358.xml
|
DDI-MedLine.d102.s6
|
DDI-MedLine.d102.s6.p0
|
The elimination half life of midazolam and triazolam also increased (1.5-2.5 fold) during coadministration with diltiazem.
|
midazolam
|
diltiazem
|
MECHANISM
|
Diltiazem_ddi.xml
|
DDI-DrugBank.d565.s34
|
DDI-DrugBank.d565.s34.p1
|
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
|
dapsone
|
saquinavir
|
MECHANISM
|
Saquinavir_ddi.xml
|
DDI-DrugBank.d124.s26
|
DDI-DrugBank.d124.s26.p30
|
Drug Interactions with Antacids Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox ) decreased fexofenadine AUC by 41% and cmax by 43%.
|
antacid
|
fexofenadine
|
NONE
|
Fexofenadine_ddi.xml
|
DDI-DrugBank.d466.s19
|
DDI-DrugBank.d466.s19.p19
|
Consider additive sedative effects and confusional states to emerge, if chlorprothixene is given with benzodiazepines or barbituates.
|
chlorprothixene
|
benzodiazepines
|
EFFECT
|
Chlorprothixene_ddi.xml
|
DDI-DrugBank.d503.s5
|
DDI-DrugBank.d503.s5.p0
|
Concomitant administration of Norpace and quinidine resulted in slight increases in plasma disopyramide levels and slight decreases in plasma quinidine levels.
|
Norpace
|
quinidine
|
MECHANISM
|
Disopyramide_ddi.xml
|
DDI-DrugBank.d506.s5
|
DDI-DrugBank.d506.s5.p0
|
Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.
|
diclofenac
|
methotrexate
|
EFFECT
|
Diclofenac_ddi.xml
|
DDI-DrugBank.d249.s5
|
DDI-DrugBank.d249.s5.p3
|
Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
|
anticoagulant
|
meprobamate
|
EFFECT
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s29
|
DDI-DrugBank.d64.s29.p15
|
Concurrent administration of low-dose dopamine HCl and diuretic agents may produce an additive or potentiating effect on urine flow.
|
dopamine HCl
|
diuretic agents
|
EFFECT
|
Dopamine_ddi.xml
|
DDI-DrugBank.d325.s2
|
DDI-DrugBank.d325.s2.p0
|
5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .
|
5HT3 Antagonists
|
granisetron
|
NONE
|
Apomorphine_ddi.xml
|
DDI-DrugBank.d357.s0
|
DDI-DrugBank.d357.s0.p5
|
If iron supplements are required during OMNICEF therapy, OMNICEF should be taken at least 2 hours before or after the supplement.
|
iron supplements
|
OMNICEF
|
NONE
|
Cefdinir_ddi.xml
|
DDI-DrugBank.d420.s6
|
DDI-DrugBank.d420.s6.p0
|
Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.
|
amitriptyline
|
phenothiazines
|
NONE
|
Duloxetine_ddi.xml
|
DDI-DrugBank.d548.s9
|
DDI-DrugBank.d548.s9.p41
|
Valproate: The addition of tiagabine to patients taking valproate chronically had no effect on tiagabine pharmacokinetics, but valproate significantly decreased tiagabine binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration.
|
valproate
|
tiagabine
|
MECHANISM
|
Tiagabine_ddi.xml
|
DDI-DrugBank.d277.s13
|
DDI-DrugBank.d277.s13.p14
|
Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).
|
barbiturates
|
divalproex sodium
|
NONE
|
Butabarbital_ddi.xml
|
DDI-DrugBank.d184.s0
|
DDI-DrugBank.d184.s0.p63
|
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.
|
diuretics
|
quinolone anti-infectives
|
NONE
|
Finasteride_ddi.xml
|
DDI-DrugBank.d209.s3
|
DDI-DrugBank.d209.s3.p109
|
Compounds in these categories result in a decreased efficacy of bromocriptine mesylate: phenothiazines, haloperidol, metoclopramide, pimozide.
|
bromocriptine mesylate
|
phenothiazines
|
EFFECT
|
Bromocriptine_ddi.xml
|
DDI-DrugBank.d272.s2
|
DDI-DrugBank.d272.s2.p0
|
However, halothane anesthetic requirement (i.e., MAC) was depressed in a dose-dependent fashion as much as 56% 1-2 hours and as much as 14% 5-6 hours after injection of ketamine, 50 mg/kg, im.
|
halothane
|
ketamine
|
MECHANISM
|
1115367.xml
|
DDI-MedLine.d16.s3
|
DDI-MedLine.d16.s3.p0
|
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride
|
VIRACEPT
|
quinidine
|
ADVISE
|
Nelfinavir_ddi.xml
|
DDI-DrugBank.d340.s6
|
DDI-DrugBank.d340.s6.p2
|
Interactions for vitamin D analogues (Vitamin D2, Vitamin D3, Calcitriol, and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;
|
vitamin D
|
Cholestyramine
|
NONE
|
Cholecalciferol_ddi.xml
|
DDI-DrugBank.d404.s0
|
DDI-DrugBank.d404.s0.p5
|
Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.
|
pimozide
|
SPRYCEL
|
ADVISE
|
Dasatinib_ddi.xml
|
DDI-DrugBank.d48.s15
|
DDI-DrugBank.d48.s15.p69
|
Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other.
|
TCAs
|
SSRIs
|
ADVISE
|
Doxepin_ddi.xml
|
DDI-DrugBank.d223.s10
|
DDI-DrugBank.d223.s10.p0
|
- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.
|
rifampin
|
vitamin D
|
NONE
|
Fosphenytoin_ddi.xml
|
DDI-DrugBank.d40.s19
|
DDI-DrugBank.d40.s19.p74
|
However, because bleeding has been reported when ibuprofen and other nonsteroidal anti-inflammatory agents have been administered to patients on coumarin-type anticoagulants, the physician should be cautious when administering ibuprofen to patients on anticoagulants.
|
nonsteroidal anti-inflammatory agents
|
ibuprofen
|
NONE
|
Ibuprofen_ddi.xml
|
DDI-DrugBank.d415.s1
|
DDI-DrugBank.d415.s1.p5
|
5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .
|
apomorphine
|
palonosetron
|
NONE
|
Apomorphine_ddi.xml
|
DDI-DrugBank.d357.s0
|
DDI-DrugBank.d357.s0.p15
|
The effects of adenosine are antagonized by methylxanthines such as caffeine and theophylline.
|
adenosine
|
theophylline
|
EFFECT
|
Adenosine_ddi.xml
|
DDI-DrugBank.d226.s4
|
DDI-DrugBank.d226.s4.p2
|
If you are also using a steroid inhaler, take bitolterol first and then wait about 15 minutes before using the steroid inhaler.
|
steroid
|
bitolterol
|
ADVISE
|
Bitolterol_ddi.xml
|
DDI-DrugBank.d560.s1
|
DDI-DrugBank.d560.s1.p0
|
Although the interactions observed in these studies do not appear to be of major clinical importance, BREVIBLOC should be titrated with caution in patients being treated concurrently with digoxin, morphine, succinylcholine or warfarin.
|
morphine
|
succinylcholine
|
NONE
|
Esmolol_ddi.xml
|
DDI-DrugBank.d422.s10
|
DDI-DrugBank.d422.s10.p7
|
Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).
|
aminoglycosides
|
HIVID
|
EFFECT
|
Zalcitabine_ddi.xml
|
DDI-DrugBank.d263.s18
|
DDI-DrugBank.d263.s18.p25
|
Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.
|
Duloxetine
|
antidepressants
|
ADVISE
|
Duloxetine_ddi.xml
|
DDI-DrugBank.d548.s9
|
DDI-DrugBank.d548.s9.p0
|
Sildenafil dose should not exceed a maximum of 25 mg in a 48- hour period in patients receiving concomitant indinavir therapy.
|
Sildenafil
|
indinavir
|
ADVISE
|
Indinavir_ddi.xml
|
DDI-DrugBank.d97.s87
|
DDI-DrugBank.d97.s87.p0
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
amitriptyline
|
tiagabine
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p167
|
- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
|
ketoprofen
|
Orudis KT
|
NONE
|
Glimepiride_ddi.xml
|
DDI-DrugBank.d521.s2
|
DDI-DrugBank.d521.s2.p130
|
Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
|
troleandomycin
|
zileuton
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s4
|
DDI-DrugBank.d94.s4.p347
|
This interaction, which has not been investigated using higher doses of fluvoxamine, may be more pronounced if a 300 mg daily dose is co-administered, particularly since fluvoxamine exhibits non-linear pharmacokinetics over the dosage range 100-300 mg. If alprazolam is co-administered with Fluvoxamine Tablets, the initial alprazolam dosage should be at least halved and titration to the lowest effective dose is recommended.
|
fluvoxamine
|
fluvoxamine
|
NONE
|
Fluvoxamine_ddi.xml
|
DDI-DrugBank.d76.s17
|
DDI-DrugBank.d76.s17.p0
|
Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.
|
antidepressants
|
tricyclic antidepressants
|
NONE
|
Duloxetine_ddi.xml
|
DDI-DrugBank.d548.s9
|
DDI-DrugBank.d548.s9.p10
|
Edema has been reported in patients concomitantly receiving Itraconazole and dihydropyridine calcium channel blockers.
|
Itraconazole
|
dihydropyridine calcium channel blockers
|
EFFECT
|
Itraconazole_ddi.xml
|
DDI-DrugBank.d165.s29
|
DDI-DrugBank.d165.s29.p0
|
Antacids increase the rate of absorption of pseudoephedrine, while kaolin decreases it.
|
pseudoephedrine
|
kaolin
|
MECHANISM
|
Azatadine_ddi.xml
|
DDI-DrugBank.d448.s6
|
DDI-DrugBank.d448.s6.p2
|
The absorption of tetracycline, furosemide, penicillin G, hydrochlorothiazide, and gemfibrozil was significantly decreased when given simultaneously with colestipol hydrochloride;
|
furosemide
|
colestipol hydrochloride
|
MECHANISM
|
Colestipol_ddi.xml
|
DDI-DrugBank.d345.s11
|
DDI-DrugBank.d345.s11.p8
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
Sporanox
|
morphine
|
NONE
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p599
|
Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.
|
caffeine
|
sedative-hypnotics
|
EFFECT
|
Butalbital_ddi.xml
|
DDI-DrugBank.d559.s1
|
DDI-DrugBank.d559.s1.p22
|
- Drugs that may either increase or decrease plasma phenytoin concentrations include: phenobarbital, vaiproic acid, and sodium valproate.
|
phenytoin
|
sodium valproate
|
MECHANISM
|
Fosphenytoin_ddi.xml
|
DDI-DrugBank.d40.s14
|
DDI-DrugBank.d40.s14.p1
|
The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin: corticosteroids, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).
|
insulin
|
corticosteroids
|
NONE
|
Insulin Glargine recombinant_ddi.xml
|
DDI-DrugBank.d527.s2
|
DDI-DrugBank.d527.s2.p0
|
Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.
|
benzodiazepines
|
barbiturates
|
EFFECT
|
Lorazepam_ddi.xml
|
DDI-DrugBank.d18.s1
|
DDI-DrugBank.d18.s1.p10
|
Vasoconstrictors: D.H.E. 45 (dihydroergotamine mesylate) Injection, USP should not be used with peripheral vasoconstrictors because the combination may cause synergistic elevation of blood pressure.
|
dihydroergotamine mesylate
|
peripheral vasoconstrictors
|
EFFECT
|
Dihydroergotamine_ddi.xml
|
DDI-DrugBank.d410.s0
|
DDI-DrugBank.d410.s0.p5
|
Therefore, patients under methotrexate therapy should be carefully monitored when concomitant ciprofloxacin therapy is indicated.
|
methotrexate
|
ciprofloxacin
|
ADVISE
|
Ciprofloxacin_ddi.xml
|
DDI-DrugBank.d123.s7
|
DDI-DrugBank.d123.s7.p0
|
Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.
|
itraconazole
|
dasatinib
|
NONE
|
Dasatinib_ddi.xml
|
DDI-DrugBank.d48.s1
|
DDI-DrugBank.d48.s1.p32
|
However, because some quinolones have been reported to enhance the effects of warfarin or its derivatives, prothrombin time or other suitable anticoagulation test should be monitored closely if a quinolone antimicrobial is administered with warfarin or its derivatives.
|
quinolone antimicrobial
|
warfarin
|
ADVISE
|
Grepafloxacin_ddi.xml
|
DDI-DrugBank.d78.s10
|
DDI-DrugBank.d78.s10.p5
|
Antihistamines may partially counteract the anticoagulation effects of heparin or warfarin.
|
Antihistamines
|
warfarin
|
EFFECT
|
Doxylamine_ddi.xml
|
DDI-DrugBank.d387.s1
|
DDI-DrugBank.d387.s1.p1
|
Quinolones, including cinoxacin, may enhance the effects of oral anticoagulants, such as warfarin or its derivatives.
|
cinoxacin
|
anticoagulants
|
EFFECT
|
Cinoxacin_ddi.xml
|
DDI-DrugBank.d562.s8
|
DDI-DrugBank.d562.s8.p3
|
Injection of estradiol 5 min before a nonlethal dose of endotoxin changed the serum sex steroid hormone response of male rats to endotoxin.
|
endotoxin
|
endotoxin
|
NONE
|
7600639.xml
|
DDI-MedLine.d39.s2
|
DDI-MedLine.d39.s2.p2
|
Naproxen, naproxen sodium and other NSAIDs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly increasing the toxicity of methotrexate.
|
Naproxen
|
methotrexate
|
MECHANISM
|
Naproxen_ddi.xml
|
DDI-DrugBank.d85.s12
|
DDI-DrugBank.d85.s12.p2
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
methadone
|
tiagabine
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p838
|
Inhibitors or substrates of CYP2D6 (i.e., quinidine, selective serotonin reuptake inhibitors [SSRIs]) may increase the plasma concentration of doxepin when administered concomitantly.
|
quinidine
|
doxepin
|
MECHANISM
|
Doxepin_ddi.xml
|
DDI-DrugBank.d223.s16
|
DDI-DrugBank.d223.s16.p2
|
Central Nervous System Depressants: The concomitant use of DURAGESIC (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
|
fentanyl
|
sedatives
|
EFFECT
|
Fentanyl_ddi.xml
|
DDI-DrugBank.d170.s5
|
DDI-DrugBank.d170.s5.p25
|
No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin, clindamycin, clofibrate, methyldopa, nicotinic acid (niacin), tolbutamide, phenytoin or warfarin.
|
colestipol hydrochloride
|
clindamycin
|
NONE
|
Colestipol_ddi.xml
|
DDI-DrugBank.d345.s13
|
DDI-DrugBank.d345.s13.p1
|
Antidepressants, tricyclic: Amphetamines may enhance the activity of tricyclic or sympathomimetic agents;
|
Amphetamines
|
tricyclic
|
EFFECT
|
Dextroamphetamine_ddi.xml
|
DDI-DrugBank.d236.s7
|
DDI-DrugBank.d236.s7.p7
|
Cholestyramine: Cholestyramine may increase the clearance of corticosteroids.
|
Cholestyramine
|
Cholestyramine
|
NONE
|
Dexamethasone_ddi.xml
|
DDI-DrugBank.d314.s10
|
DDI-DrugBank.d314.s10.p0
|
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
|
nondepolarizing agents
|
procainamide
|
EFFECT
|
Cisatracurium Besylate_ddi.xml
|
DDI-DrugBank.d60.s12
|
DDI-DrugBank.d60.s12.p13
|
When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.
|
azithromycin
|
triazolam
|
MECHANISM
|
Azithromycin_ddi.xml
|
DDI-DrugBank.d53.s7
|
DDI-DrugBank.d53.s7.p11
|
Steady-state bosentan plasma concentrations were 3- to 4-fold higher than in the absence of cyclosporine A.
|
bosentan
|
cyclosporine A
|
MECHANISM
|
Bosentan_ddi.xml
|
DDI-DrugBank.d289.s11
|
DDI-DrugBank.d289.s11.p0
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
ethosuximide
|
praziquantel
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p616
|
Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.
|
clarithromycin
|
nefazodone
|
NONE
|
Dasatinib_ddi.xml
|
DDI-DrugBank.d48.s1
|
DDI-DrugBank.d48.s1.p45
|
Because of the small effect on half-life, the coadministration with probenecid to extend the half-life of ertapenem is not recommended.
|
probenecid
|
ertapenem
|
ADVISE
|
Ertapenem_ddi.xml
|
DDI-DrugBank.d329.s3
|
DDI-DrugBank.d329.s3.p0
|
Substances that are potent inhibitors of CYP3A4 activity (eg, ketoconazole and itraconazole) decrease gefitinib metabolism and increase gefitinib plasma concentrations.
|
ketoconazole
|
gefitinib
|
MECHANISM
|
Gefitinib_ddi.xml
|
DDI-DrugBank.d207.s4
|
DDI-DrugBank.d207.s4.p1
|
Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.
|
Beta-blockers
|
PROLEUKIN
|
EFFECT
|
Aldesleukin_ddi.xml
|
DDI-DrugBank.d114.s10
|
DDI-DrugBank.d114.s10.p19
|
Possible drug interactions of HUMORSOL with succinylcholine or with other anticholinesterase agents.
|
HUMORSOL
|
anticholinesterase agents
|
INT
|
Demecarium bromide_ddi.xml
|
DDI-DrugBank.d149.s0
|
DDI-DrugBank.d149.s0.p1
|
In eight HIV-infected patients, the steady-state AUC of ciprofloxacin was decreased an average of 26% (95% CI = 14%, 37%) when ciprofloxacin was administered 2 hours prior to a marketed chewable/dispersible tablet formulation of VIDEX.
|
ciprofloxacin
|
VIDEX
|
MECHANISM
|
Didanosine_ddi.xml
|
DDI-DrugBank.d43.s9
|
DDI-DrugBank.d43.s9.p2
|
Nabilone should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including alcohol, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).
|
Nabilone
|
psychoactive drugs
|
ADVISE
|
Nabilone_ddi.xml
|
DDI-DrugBank.d552.s0
|
DDI-DrugBank.d552.s0.p0
|
Accordingly, diazepam and fluvoxamine should not ordinarily be co-administered.
|
diazepam
|
fluvoxamine
|
ADVISE
|
Fluvoxamine_ddi.xml
|
DDI-DrugBank.d76.s25
|
DDI-DrugBank.d76.s25.p0
|
Cholestyramine-Concomitant intake of cholestyramine and vitamin K may reduce the absorption of vitamin K.
|
Cholestyramine
|
cholestyramine
|
NONE
|
Menadione_ddi.xml
|
DDI-DrugBank.d139.s3
|
DDI-DrugBank.d139.s3.p0
|
Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.
|
quinolones
|
VIDEX
|
MECHANISM
|
Grepafloxacin_ddi.xml
|
DDI-DrugBank.d78.s1
|
DDI-DrugBank.d78.s1.p9
|
Drug Interaction During Pregnancy: Cromolyn sodium and isoproterenol were studied following subcutaneous injections in pregnant mice.
|
Cromolyn sodium
|
isoproterenol
|
NONE
|
Cromoglicate_ddi.xml
|
DDI-DrugBank.d229.s0
|
DDI-DrugBank.d229.s0.p0
|
Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.
|
Levo-Dromoran
|
alcohol
|
EFFECT
|
Levorphanol_ddi.xml
|
DDI-DrugBank.d257.s0
|
DDI-DrugBank.d257.s0.p1
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
Etonogestrel
|
phenylbutazone
|
INT
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p35
|
Digoxin: In controlled studies in healthy volunteers, bepridil hydrochloride either had no effect (one study) or was associated with modest increases, about 30% (two studies) in steady-state serum digoxin concentrations.
|
bepridil hydrochloride
|
digoxin
|
MECHANISM
|
Bepridil_ddi.xml
|
DDI-DrugBank.d137.s4
|
DDI-DrugBank.d137.s4.p2
|
Coadministration of valdecoxib and Ortho-Novum 1/35 increased the exposure of norethindrone and ethinyl estradiol by 20% and 34%, respectively.
|
Ortho-Novum
|
ethinyl estradiol
|
NONE
|
Valdecoxib_ddi.xml
|
DDI-DrugBank.d328.s44
|
DDI-DrugBank.d328.s44.p4
|
Particular caution should be observed with digitalis preparations since there are conflicting results for the effect of colestipol hydrochloride on the availability of digoxin and digitoxin.
|
colestipol hydrochloride
|
digoxin
|
MECHANISM
|
Colestipol_ddi.xml
|
DDI-DrugBank.d345.s14
|
DDI-DrugBank.d345.s14.p3
|
Chlorthalidone and related drugs may decrease arterial responsiveness to norepinephrine.
|
Chlorthalidone
|
norepinephrine
|
EFFECT
|
Chlorthalidone_ddi.xml
|
DDI-DrugBank.d265.s8
|
DDI-DrugBank.d265.s8.p0
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.